Insulet CEO Called Omnipod 5 “Reliable” and a “Favorite Pump” on February 18 — Two Weeks Later, the Company Disclosed a Voluntary Recall Covering Thousands of Defective Pods
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — On February 18, 2026, Insulet Corp. (NASDAQ: PODD) CEO Ashley McEvoy told investors on the Q4 2025 earnings call that “our results in the fourth quarter are a testament to the reliability, consistency and broad appeal of Omnipod.” On March 12, 2026, the Company filed an 8-K disclosing a voluntary medical-device correction for Omnipod 5 pods due to an insulin-leakage defect linked to eighteen serious adverse events — and PODD shares fell 6.9%. Shareholders who lost money on PODD are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
During that same February 18 earnings call, McEvoy stated that “strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence” and described Omnipod 5 as the “favorite pump” for both type-1 and type-2 users in 2025. CFO Flavia Pease added that U.S. revenue growth was “above the high end of our guidance range, driven by continued demand for Omnipod 5 across type 1 and type 2 customers.” At no point during the call did any executive reference a product-quality issue, a pending regulatory action, or an anticipated recall.
Only a few weeks later, the March 12 filing revealed a defect affecting Omnipod 5 Pods. The filing identified insulin leakage capable of causing diabetic ketoacidosis — a serious medical emergency. The Company’s February 18 statements about Omnipod reliability, patient confidence, and demand-driven growth had not referenced any of these issues.
If you purchased Insulet Corp. shares and suffered a loss, click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
